Redeye is encouraged by the continued momentum in Nexstim and path towards profitability, although with a somewhat new focus following the recent licensing agreement. We slightly increase our base case to SEK 67,5 per share but could adjust further as we learn more about the plans for collaborator Magnus Medical.

https://www.redeye.se/research/835196/nexstim-h221-report-follow-up-comment?utm_source=finwire&utm_medium=RSS

Redeye